AdV-tk

Phase 3Biologic

CCandel Therapeutics, Inc.

AdV-tk is one of 172 biologic programs targeting Glioma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

171

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Liver TransplantActive, not recruiting

Pleural EffusionActive, not recruiting

Malignant GliomaActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

GliomaPhase 1

Active, not recruiting

Liver TransplantPhase 3

Active, not recruiting

Pleural EffusionPhase 1

Active, not recruiting

Malignant GliomaPhase 1

Active, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

AdV-tk

CCandel Therapeutics, Inc.

Phase 3

1 2

Viread

Gilead

Preclinical

1 3

Ibrance

Pfizer

Preclinical

1 4

Sovaldi

Gilead

Preclinical

1 5

Hepsera

Coreg

2 7

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Preclinical

16 8

Doptelet

AAkarx

Preclinical

1 9

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 10

Vermox

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Malignant Glioma1 trial

Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas

Completed·CCandel Therapeutics, Inc.·Phase 1·NCT00751270·15 enrolled

Liver Transplant1 trial

Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC

Unknown status·HHuazhong University of Science and Technology·Phase 3·NCT03313596·180 enrolled

Pediatric Brain Tumor1 trial

A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors

Completed·CCandel Therapeutics, Inc.·Phase 1·NCT00634231·8 enrolled

Pleural effusion1 trial

Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion

Completed·CCandel Therapeutics, Inc.·Phase 1·NCT01997190·19 enrolled

Hepatocellular Carcinoma1 trial

Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma

Completed·HHuazhong University of Science and Technology·Phase 2·NCT02202564·81 enrolled

2 more indications

Glioma1 trial

GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas

Completed·CCandel Therapeutics, Inc.·Phase 1·NCT03576612·41 enrolled

Pancreas Cancer1 trial

AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

Completed·CCandel Therapeutics, Inc.·Phase 1·NCT00638612·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for AdV-tk. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AdV-tk compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AdV-tk. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Candel Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: CCandel Therapeutics, Inc.

AdV-tk

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Malignant Glioma1 trial

Liver Transplant1 trial

Pediatric Brain Tumor1 trial

Pleural effusion1 trial

Hepatocellular Carcinoma1 trial

Glioma1 trial

Pancreas Cancer1 trial

References

Drug Info

Quick Facts

Related News